Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
Merck
Express Scripts
Colorcon

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR PONATINIB HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ponatinib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00660920 ↗ Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Completed Ariad Pharmaceuticals Phase 1 2008-06-01 The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
NCT01207440 ↗ Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Completed Ariad Pharmaceuticals Phase 2 2010-09-30 The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation.
NCT01424982 ↗ Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Recruiting Ariad Pharmaceuticals Phase 2 2011-10-05 This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia.
NCT01424982 ↗ Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Recruiting M.D. Anderson Cancer Center Phase 2 2011-10-05 This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia.
NCT01549548 ↗ Compassionate Use Ponatinib No longer available Ariad Pharmaceuticals 1969-12-31 The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.
NCT01549548 ↗ Compassionate Use Ponatinib No longer available OHSU Knight Cancer Institute 1969-12-31 The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ponatinib Hydrochloride

Condition Name

Condition Name for Ponatinib Hydrochloride
Intervention Trials
Acute Lymphoblastic Leukemia 10
Chronic Myeloid Leukemia 9
Leukemia 8
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ponatinib Hydrochloride
Intervention Trials
Leukemia 43
Leukemia, Myeloid 32
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29
Precursor Cell Lymphoblastic Leukemia-Lymphoma 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ponatinib Hydrochloride

Trials by Country

Trials by Country for Ponatinib Hydrochloride
Location Trials
United States 187
France 28
Italy 21
China 20
Japan 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ponatinib Hydrochloride
Location Trials
Texas 19
Oregon 12
California 10
Maryland 9
Michigan 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ponatinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ponatinib Hydrochloride
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 1
Phase 2 36
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ponatinib Hydrochloride
Clinical Trial Phase Trials
Recruiting 24
Completed 10
Active, not recruiting 8
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ponatinib Hydrochloride

Sponsor Name

Sponsor Name for Ponatinib Hydrochloride
Sponsor Trials
Ariad Pharmaceuticals 16
National Cancer Institute (NCI) 10
M.D. Anderson Cancer Center 9
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ponatinib Hydrochloride
Sponsor Trials
Other 52
Industry 32
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Baxter
McKesson
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.